LabGenius raises $10M to use AI for protein drug discovery

LabGenius, a London-based startup applying AI and “robotic automation” to protein drug discovery, has raised $10 million in Series A funding. The round is led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Air Street Capital and existing investors. Also investing is Recursion Pharmaceuticals’ founder and CEO Chris Gibson, as […]


23 Oct, 2019TECHCRUNCH.COM

LabGenius raises $10M to use AI for protein drug discovery

LabGenius, a London-based startup applying AI and “robotic automation” to protein drug discovery, has raised $10 million in Series A funding.

The round is led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Air Street Capital and existing investors. Also investing is Recursion Pharmaceuticals’ founder and CEO Chris Gibson, as well as Inovia Capital General Partner Patrick Pichette, who was formerly Google’s CFO.

Lux Capital’s Zavain Dar and Obvious Ventures’ Nan Li will join the LabGenius board of directors. Notably, the U.K. company’s early investors include Nathan Benaich, Torsten Reil, EF’s Matt Clifford, and Philipp Moehring, to name just a few....

This article is only available for BEAMSTART community members. Please log in to view it. Registration is free of charge.

TechCrunchAuthor

Breaking technology news and analysis. The number one guide for all things tech.

Share this Story


More Stories


BEAMSTART News covers the latest stories on Business, Finance, and Opportunities in Asia. We are an extension of global partnerships platform BEAMSTART.

Stay updated with us via our channels below:

 

Download the App

Be part of the global community of CEOs, Business Leaders, and Professionals. Download below to instantly form partnerships and discover opportunities:

© 2016 - 2020 BEAMSTART. All Rights Reserved.